<?xml version='1.0' encoding='utf-8'?>
<document id="17357590"><sentence text="The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study."><entity charOffset="17-28" id="DDI-PubMed.17357590.s1.e0" text="simvastatin" /><entity charOffset="46-55" id="DDI-PubMed.17357590.s1.e1" text="diltiazem" /><pair ddi="false" e1="DDI-PubMed.17357590.s1.e0" e2="DDI-PubMed.17357590.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17357590.s1.e0" e2="DDI-PubMed.17357590.s1.e1" /></sentence><sentence text="3-Hydroxy-3-methyl-glytaryl coenzyme A (HMG-CoA) reductase inhibitors (&quot;statins&quot;) have been proved to be extremely useful in the management of hypercholesterolemia, as well as in prevention of primary and secondary coronary heart disease"><entity charOffset="0-38" id="DDI-PubMed.17357590.s2.e0" text="3-Hydroxy-3-methyl-glytaryl coenzyme A" /></sentence><sentence text=" However, they may produce rare but severe muscle-related symptoms such as myopathy and rhabdomyolysis" /><sentence text=" Recent findings in vitro have shown that statins can reduce cardiomyocyte viability" /><sentence text=" The exact mechanism of statin myotoxicity still remains unclear" /><sentence text=" Diltiazem as CYP3A4 inhibitor, is a well recognized risk factor of skeletal muscles myopathy, if co-administered with simvastatin"><entity charOffset="119-130" id="DDI-PubMed.17357590.s6.e0" text="simvastatin" /></sentence><sentence text=" It is not known whether such interaction affects myocardial efficiency causing biochemical changes" /><sentence text=" The experiments were performed on thirty six New Zealand white rabbits" /><sentence text=" The animals were divided into four groups receiving: 0" /><sentence text="2% MC (control group): diltiazem (5 mg/kg); simvastatin (50 mg/kg) or diltiazem + simvastatin, daily for 14 days (po)"><entity charOffset="44-55" id="DDI-PubMed.17357590.s10.e0" text="simvastatin" /><entity charOffset="70-93" id="DDI-PubMed.17357590.s10.e1" text="diltiazem + simvastatin" /><pair ddi="false" e1="DDI-PubMed.17357590.s10.e0" e2="DDI-PubMed.17357590.s10.e0" /><pair ddi="false" e1="DDI-PubMed.17357590.s10.e0" e2="DDI-PubMed.17357590.s10.e1" /></sentence><sentence text=" The following biochemical parameters were estimated: creatine kinase (CK), serum transaminases (ALT and AST), as well as myocardial injury markers: troponin I (Tnl) and creatine kinase MB (CK-MB)"><entity charOffset="54-62" id="DDI-PubMed.17357590.s11.e0" text="creatine" /></sentence><sentence text=" Simultaneous administration of simvastatin and diltiazem caused 23-fold increase (p &lt; 0"><entity charOffset="32-43" id="DDI-PubMed.17357590.s12.e0" text="simvastatin" /></sentence><sentence text="01), in rabbit serum CK levels and 20-fold increase (p = 0" /><sentence text="056) in TnI levels, as compared to the initial values" /><sentence text=" Also in these rabbits significant increase in CK (12411,60 vs 839" /><sentence text="87 IU/L) and TnI (0,26 vs 0,014 ng/mL), as compared to control group were observed" /><sentence text=" Significant increase in CK (12411,60 vs 1100,92 IU/L) and TnI (0,26 vs 0,012 ng/mL), as compared to diltiazem alone were noted, too" /><sentence text=" This may suggest another mechanism of drug-drug interaction than the one based on CYP3A4 inhibition if the impact on cardiac or skeletal muscle is considered" /><sentence text="" /></document>